Morgan Stanley’s Lunai Bioworks LNAI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.07K | Sell |
326
-1
| -0.3% | -$3 | ﹤0.01% | 7501 |
|
|
2026
Q1 | $1.06K | Hold |
327
| – | – | ﹤0.01% | 7425 |
|
|
2025
Q4 | $2.3K | Sell |
327
-1
| -0.3% | -$9 | ﹤0.01% | 7219 |
|
|
2025
Q3 | $3.72K | Sell |
328
-437
| -57% | -$8.42K | ﹤0.01% | 7163 |
|
|
2025
Q2 | $17.7K | Sell |
765
-1,844
| -71% | -$51.5K | ﹤0.01% | 6686 |
|
|
2025
Q1 | $113K | Sell |
2,609
-1,993
| -43% | -$128K | ﹤0.01% | 5953 |
|
|
2024
Q4 | $308K | Buy |
4,602
+144
| +3% | +$9.6K | ﹤0.01% | 5628 |
|
|
2024
Q3 | $172K | Sell |
4,458
-1,222
| -22% | -$84.7K | ﹤0.01% | 5802 |
|
|
2024
Q2 | $795K | Buy |
5,680
+989
| +21% | +$135K | ﹤0.01% | 5090 |
|
|
2024
Q1 | $995K | Buy |
4,691
+154
| +3% | +$41.5K | ﹤0.01% | 4957 |
|
|
2023
Q4 | $1.15M | Buy |
4,537
+2,866
| +172% | +$785K | ﹤0.01% | 4846 |
|
|
2023
Q3 | $598K | Buy |
1,671
+1,091
| +188% | +$166K | ﹤0.01% | 5084 |
|
|
2023
Q2 | $26.3K | Sell |
580
-365
| -39% | -$28K | ﹤0.01% | 6468 |
|
|
2023
Q1 | $69.2K | Buy |
945
+53
| +6% | +$4.66K | ﹤0.01% | 6151 |
|
|
2022
Q4 | $73.5K | Sell |
892
-969
| -52% | -$130K | ﹤0.01% | 6115 |
|
|
2022
Q3 | $269K | Buy |
1,861
+241
| +15% | +$43.9K | ﹤0.01% | 5583 |
|
|
2022
Q2 | $250K | Buy |
1,620
+958
| +145% | +$438K | ﹤0.01% | 5786 |
|
|
2022
Q1 | $437K | Sell |
662
-1,041
| -61% | -$554K | ﹤0.01% | 5493 |
|
|
2021
Q4 | $994K | Sell |
1,703
-6
| -0.4% | -$4.36K | ﹤0.01% | 5068 |
|
|
2021
Q3 | $920K | Buy |
1,709
+1,472
| +621% | +$719K | ﹤0.01% | 5101 |
|
|
2021
Q2 | $93K | Sell |
237
-2
| -0.8% | -$652 | ﹤0.01% | 6396 |
|
|
2021
Q1 | $67K | Sell |
239
-124
| -34% | -$36.5K | ﹤0.01% | 6211 |
|
|
2020
Q4 | $86K | Buy |
363
+340
| +1,478% | +$85.9K | ﹤0.01% | 5970 |
|
|
2020
Q3 | $6K | Sell |
23
-38
| -62% | -$12K | ﹤0.01% | 6416 |
|
|
2020
Q2 | $21K | Buy |
61
+38
| +165% | +$11.5K | ﹤0.01% | 5997 |
|
|
2020
Q1 | $6K | Sell |
23
-216
| -90% | -$64.2K | ﹤0.01% | 6156 |
|
|
2019
Q4 | $96K | Buy |
239
+217
| +986% | +$95.4K | ﹤0.01% | 5666 |
|
|
2019
Q3 | $9K | Buy |
22
+13
| +144% | +$4.97K | ﹤0.01% | 6245 |
|
|
2019
Q2 | $3K | Sell |
9
-38
| -81% | -$18.5K | ﹤0.01% | 6414 |
|
|
2019
Q1 | $26K | Buy |
+47
| New | +$27.5K | ﹤0.01% | 5927 |
|
Other funds holding LNAI
GSC
Morgan Stanley's LNAI Position: Q2 2026 in Review
Morgan Stanley reduced its Lunai Bioworks (LNAI) stake by 0.31% in Q2 2026, selling an estimated $3 and leaving 326 shares worth $1.07K. The position accounts for ﹤0.01% of the portfolio, ranked #7501.
Morgan Stanley first reported a position in LNAI in Q1 2019 and has held it in 30 quarters since. The position peaked at $1.15M in Q4 2023. 16 funds tracked by Wall St. Rank hold LNAI as of Q2 2026.
- Morgan Stanley held 326 shares of Lunai Bioworks worth $1.07K as of Q2 2026.
- Morgan Stanley sold 1 Lunai Bioworks share in Q2 2026, an estimated $3.
- Lunai Bioworks made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #7501 holding.
- Morgan Stanley first reported a position in Lunai Bioworks in Q1 2019 and has held it in 30 quarters since.
- Morgan Stanley's Lunai Bioworks position peaked at $1.15M in Q4 2023.
- 16 funds tracked by Wall St. Rank held Lunai Bioworks as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.